Cogent Biosciences Inc’s recent filing unveils that its Chief Commercial Officer Pinnow Cole acquired Company’s shares for reported $0.33 million on Jan 14 ’25. In the deal valued at $7.60 per share,43,750 shares were bought. As a result of this transaction, Pinnow Cole now holds 45,848 shares worth roughly $0.32 million.
Scotiabank initiated its Cogent Biosciences Inc [COGT] rating to a Sector outperform in a research note published on March 07, 2025; the price target was $17. A number of analysts have revised their coverage, including Needham’s analysts, who decreased its forecast for the stock in mid December from “a Buy” to “a Hold”. Robert W. Baird also remained covering COGT and has decreased its forecast on February 26, 2024 with a “Neutral” recommendation from previously “an Outperform” rating. Citigroup started covering the stock on February 08, 2024. It rated COGT as “a Buy”.
Price Performance Review of COGT
On Friday, Cogent Biosciences Inc [NASDAQ:COGT] saw its stock fall -1.94% to $7.08. Over the last five days, the stock has gained 4.12%. Cogent Biosciences Inc shares have fallen nearly -9.23% since the year began. Nevertheless, the stocks have fallen -19.73% over the past one year. While a 52-week high of $12.61 was reached on 01/30/25, a 52-week low of $3.72 was recorded on 04/09/25.
Levels Of Support And Resistance For COGT Stock
The 24-hour chart illustrates a support level at 6.88, which if violated will result in even more drops to 6.68. On the upside, there is a resistance level at 7.28. A further resistance level may holdings at 7.48.
How much short interest is there in Cogent Biosciences Inc?
A steep rise in short interest was recorded in Cogent Biosciences Inc stocks on 2025-05-30, dropping by -0.38 million shares to a total of 14.31 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-30 was 14.68 million shares. There was a decline of -2.64%, which implies that there is a negative sentiment for the stock.
